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Evidence of taurine depletion and accumulation of cysteinesulfinic acid
in chronic dialysis patients. Methionine, taurine and cysteinesulfinic acid
(CSA) were determined by reversed-phase high-performance liquid chro-
matography (RP-HPLC) in plasma from ten patients treated with hemo-
dialysis (HD) and eight patients treated with continuous ambulatory
peritoneal dialysis (CAPD). The patients' data were compared with data
obtained from ten healthy controls. Significant reductions in plasma
taurine levels were observed in the RD patients (34 13 jtmol/liter,
mean SD) and the CAPD patients (47 12 j.mol/liter) compared to the
controls (66 5 itmol/liter), while the CSA levels were markedly higher
in the I-ID patients (9.1 2.8 mol/liter) and the CAPD patients (9.1
2.4 j.mol/liter) than in the controls (0.79 0.15 jmol/liter). A single HD
treatment significantly reduced the plasma taurine and CSA concentra-
tions (P <0.01 and P <0.001), respectively. The plasma methionine levels
were normal in both patient groups. The finding of a low plasma taurine
level and a large accumulation of CSA suggests that the metabolic
conversion of CSA to taurinc is impaired in uremic patients and this
metabolic abnormality may cause taurine depletion.
Patients with chronic renal failure (GRE) exhibit various ab-
normalities in extracellular and intracellular amino acid profiles.
Some of the changes are ascribed to uremia per se or impaired
renal degradation or deficient excretory and metabolic functions
in the diseased kidney, but other abnormalities may reflect
inadequate nutritional intake or malnutrition [1—5]. In dialysis
patients, the loss of protein and amino acids due to the dialysis
procedure may also contribute to such abnormalities [6].
Abnormal values of sulfur amino acids in CRF have been
reported in many studies. In most of them the plasma concentra-
tion of methionine has been normal in untreated uremic patients
[7—9] and dialyzed uremic patients [4, 6, 10, 11]. Furthermore,
accumulations of eysteine and homocy.steine in the plasma have
been noted in untreated uremic patients and in those on hemo-
dialysis (HD) [11—141.
Taurine (2-aminoethanesulfonic acid) is an end product of the
metabolism of sulfur amino acids [151 and it is one of the most
abundant free amino acids in the human body [16]. The major
pathway for the biosynthesis of taurine (Fig. 1) is that via
cysteinesulfinic acid (GSA), and this pathway depends on vitamin
B6, in the form of pyridoxal—5'-phosphate, which is required as a
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coenzyme for cysteinesulfinic acid decarboxylase (CSAD) [17],
which is a rate-limiting enzyme in the conversion of GSA to
taurine.
In several studies where plasma taurine concentrations have
been examined in patients with CRF, who either were not
dialyzed or had undergone maintenance dialysis, the taurine level
was found to be low [4, 6, 18, 19]. However, normal or elevated
levels have been reported [10, 11, 20].
The present study was designed to evaluate further the concen-
trations of plasma taurine and some of its precursors in ten
patients on HD treatment and in eight patients on continuous
ambulatory peritoneal dialysis (CAPD). In HD patients, the
amino acid concentrations were evaluated before and after dial-
ysis. Free amino acids in plasma were determined with reversed-
phase high-performance liquid chromatography (RP-HPLG). The
results showed low plasma taurine concentrations, despite an
accumulation of GSA in these uremic patients.
Methods
Study population
Ten patients with CRF, six males with a mean age of 67 (range
60 to 81) years and four females with a mean age of 73 (64 to 79)
years, underwent HD for 9 to 168 (mean 42) months. The etiology
of CRF and the numbers of patients in each category were as
follows: chronic glomerulonephritis 4, chronic pyelonephritis 1,
diabetic nephropathy 1, nephrosclerosis 1, polycystic kidney I and
two cases of renal disease of undetermined etiology.
Eight patients, five males with a mean age of 53 (range 30 to 70)
years and three females with a mean age of 54 (range 47 to 75)
years, were studied after 5 to 47 (mean 23) months of treatment
with CAPD. One of the patients had been on HD treatment for 15
months and was then treated with a low protein diet for 60 months
before he started GAPD treatment. The causes of CRF were
chronic glomcrulonephritis in five patients, hypertensive nephrop-
athy, nephrosclerosis and renal failure of unknown etiology in one
patient each.
All patients were receiving various medications, mainly antihy-
pertensive agents, diuretics, sodium bicarbonate, calcium carbon-
ate and all were prescribed a daily supplement of water-soluble
vitamins, including pyridoxine 10 mg/day. None of the patients
was treated with corticosteroids or cytotoxic drugs. All had normal
transaminase levels in plasma and no signs of liver disease.
Ten healthy volunteers, four males with a mean age of 39
(range 31 to 44) years and six females with a mean age of 38 (27
to 53) years, were selected for comparative analysis in the present
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Table 1. Clinical characteristics and biochemistries of uremic patients
and healthy subjects (mean SD)
HD
Controls
N = 10
N = 10
Pre-HD Post-HD
CAPD
N = 8
Sex male/female 4/6 6/4 5/3
Age years 38 8 69 7 55 15
Weight kg 67 13 67 13 67 13
Heightcm 169±7 172±8 170±9
Body mass index 24 4 23 5 23 3
nPNAg/kg body wt/day — 1.34 0.30 1.09 0.20
Serum albumin g/liter 35—46° 32 3 — 35 5
Serum creatinine 90 13 754 140 322 75 764 140
pinol/liter
Serum urea mmol/liter 5 1 28 7 9 3 23 11
Creatinine clearance 112 14 — —
mI/mm
Urea clearance mI/mm 59 17 — —
Abbreviation is: nPNA, normalized protein equivalent of total nitrogen
appearance.
Normal range of serum albumin in the clinical laboratory of the
hospital
study and for determinations of urinary excretion and clearance of
CSA and taurine.
The clinical characteristics and routine biochemistries of the
patients and controls are presented in Table 1. The serum
albumin level tended to be low in the uremic patients. The protein
equivalent of total nitrogen appearance (nPNA) was calculated
from the urea appearance rate [21, 22]. The mean values were
above 1 g/kg body wt/day in both the HD and the CAPD patients.
Blood samples were obtained from a peripheral vein in CAPD
patients and normal subjects and from a vascular access fistula in
HD patients at the onset and termination of dialysis. Blood was
drawn in the morning, after the patients and healthy subjects had
fasted overnight. The post-dialysis samples were drawn four hours
later from HD patients who had continued fasting until the end of
the dialysis session.
Blood was collected in evacuated tubes containing heparin and
was centrifuged immediately at 2300 x g for 15 minutes at 4°C
and the upper part of the supernatant was removed with a pipette,
leaving a 5 mm layer next to the blood cells in order to avoid
contamination of amino acids released from blood cells and
thereby minimize artefactual elevation of the plasma taurine level
[23]. Plasma was quickly deproteinized by mixing 1 ml of plasma
with 100 il 5-sulfosalicylic acid (30%), including L-norvaline (2
mM) as an internal amino acid standard. The samples were kept at
4°C for one hour, then centrifuged at 2300 X g for 20 minutes at
4°C and the supernatant was pipetted and filtered through a 0.45
m membrane filter (Millipore, Nilhon Millipore, Kogyo K.K.,
Japan). All samples were stored at —70°C until the amino acids
were analyzed.
For the analysis of sulfur amino acids in the urine of healthy
subjects, four-hour urine samples, collected in the morning of the
day when the blood samples were obtained, were frozen at —70°C
until the day of analysis, when they were processed similarly to the
deproteinized plasma samples, after addition of the internal
standard.
The protocol of the study was approved by the Ethics Commit-
tee at Karolinska Institute, Huddinge University Hospital, Stock-
holm, and informed consent was obtained from each patient and
control subject.
Analytical methods
The determinations of amino acids in plasma and urine were
carried out using RP-HPLC and fluorometric detection. The
method was based on automated pre-column derivitization of
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HD
Controls
N = 10
N = 10
._________ CAPD
N = 8Pre-HD Post-HD
Methionine 31 5 30 5 28 6 29 4
Cysteinesulfinic acid
Taurine
0.79 0.15
66 5
9.1 2.8°
34 13'
2.4 0.6°"
20 + 5ad
9.1 2.4"
47 12L
Taurine/CSA ratio 85 16 4.2 2.8" 8.6 2.1"' 5.4 1.8"
amino acids with orthophthalaldehyde (OPA)/3-mercaptopropi-
onic acid (3-MPA) [241. The derivitizing stock solution was
prepared by dissolving 50 mg anhydrous OPA in 4.5 ml of
methanol to which 0.5 ml of 1.0 M borate buffer of pH 10.4 were
added. To this mixture, 50 1.d of 3-MPA were added. The stock
solution was kept in the dark at 4°C. The working solution was
prepared on the day of analysis by adding 100 .tl of the stock
solution to 900 j.d borate buffer. The mobile phases used were
solvent A [12.5 m phosphate buffer adjusted to pH 6.93 with
NaOH, and tetrahydrofuran 99:1 (vol:vol)I and solvent B [meth-
anol, acetonitrile and deionized water 35:15:50 (vol:vol)]. Fluoro-
metric detection was performed at Ex = 340 nm and Em = 450
nm.
The automated HPLC mixed 30 j.d of OPA with 30 .d of the
sample for two minutes before injection. The whole chromato-
graphic run lasted for 54 minutes, including eight minutes of
re-equilibration with solvent A. The flow rate was maintained at 1
ml through the chromatographic run, except in the first minute
when it increased linearly from 0.8 to 1 ml. The elution profile was
as follows: 0 to 1 minute, 10% B; ito 30 minutes, 75% B; 30 to 43
minutes, 90% B; 43 to 45 minutes, 100% B; 45 to 46 minutes, 0%
B linear gradient.
The HPLC system (Waters Associate, Milford, MA, USA)
consisted of a Waters system controller model 600E with the two
pumps M-45 model, the auto-sampler WISP-712B with cooling
system to optimize the temperature at +4°C and a Waters 470
fluorescence detector model. The amino acids were separated on
a reversed-phase C18 YMC column, 4.6 X 150 mm in length
(YMC Co. Ltd, Kyoto, Japan). The chromatograms were inte-
grated in a computerized data system (Chromatography Data
Systems AB, Stockholm).
Serum creatinine, serum urea and serum albumin concentra-
tions were determined by routine biochemical laboratory methods
(Table 1) in the clinical laboratory at the hospital, using a Hitachi
737 Automatic Analyzer (Naka Works, Hitachi Ltd., Tokyo,
Japan).
Statistical methods
The differences between the control and the 2 patient groups
were determined with the nonparametric Mann-Whitney test. The
differences between the prehemodialysis and posthemodialysis
samples were determined by using the paired t-test, A P value <
0.05 was considered significant. Linear regression analysis was
used to test the correlation between the different variables. All
values are expressed as (mean SD).
Excretion pjnol/hr 2.02 1.02 30.7 16.1
Renal clearance mI/mm 43.4 19.3 10.3 6.5
Results
The plasma concentrations of sulfur amino acids in control and
patient groups and the effect of a single HD treatment as well as
the ratio of taurine to CSA are shown in Table 2.
In CAPD patients and in predialysis samples of HD patients,
the plasma concentrations of taurine were lower than in normal
subjects (P < 0.01 and P < 0.001, respectively). A single HD
treatment reduced the plasma taurine significantly (predialysis vs.
postdialysis, P < 0.01).
Plasma CSA levels were significantly elevated in CAPD patients
and predialysis samples of HD patients (P < 0.001 and P < 0.001,
respectively). After a single HD treatment, there was a significant
reduction in the CSA plasma level (predialysis vs. postdialysis,
P < 0.001).
No significant changes in plasma methionine levels occurred in
CAPD patients or HD patients, as compared to normal subjects.
Two values of postdialysis plasma methionine concentrations
from two HD patients were excluded because they were spuri-
ously high, due to difficulties in the technical separation. No
significant reductions in the plasma methionine levels were ob-
served after a single dialysis treatment.
The ratio of taurine to CSA was significantly reduced in
predialysis samples of HD patients and CAPD patients, as
compared to healthy controls (P < 0.001), whereas the ratio
between prehemodialysis and posthemodialysis had increased
(P < 0.05).
The urinary excretion and renal clearance of taurine and CSA
in the control group are presented in Table 3. The urinary
excretion of CSA in healthy volunteers was 2,02 j.rmol/hr and the
CSA clearance (43.4 mI/mm) was about 38% of the creatinine
clearance. The taurine clearance (10.3 mI/mm) was about 9% of
the creatinine clearance and the urinary excretion of taurine was
30.7 mol/hr, which was about 737 imol/day.
The non-sulfur free amino acids in plasma were also measured
by the same method. The sums of the concentrations of the
essential amino acids (EAA), the non-essential amino acids
(NEAA) and the branched-chain amino acids (BCAA) are
presented in Table 4. EAA and BCAA were significantly
reduced in HD patients (P <0.001 andP <0.01, respectively) and
in CAPD patients (P < 0.01). NEAA were significantly elevated
(P < 0.05) in CAPD patients but were unchanged in HD patients,
as compared to the control group. There were no correlations
between the plasma taurine and EAA, BCAA or INEAA
levels, respectively.
The serum albumin level tended to be lower in the patient
groups (Table 1), but it did not correlate with the low plasma
taurine levels.
Discussion
In this study, the plasma taurine concentrations were low in
uremic patients treated with CAPD or HD. Markedly elevated
plasma CSA levels were observed (Table 2). CSA is an interme-
diate precursor of taurine synthesis. On the other hand, methio-
nine, which is an essential amino acid and one of the precursors of
Table 2. Plasma sulfur free amino acid concentrations (jtmol/liter
mean SD) in uremic patients and control subjects
Table 3. Urinary excretion and renal clearance of taurine and
cystcinesulfinic acid in 10 healthy controls (mean SD)
CSA Taurine
Statistical significance: aP < 0.001 when compared to controls, h p <
0.01 when compared to controls, "P < 0.001 when compared to Pre-HD,dP < 0.01 when compared to pre-HD, and P < 0.05 when compared to
pre-HD
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Table 4. Essential, branched-chain and non-essential amino acid
concentrations (rmol/liter mean SD) in uremic patients and healthy
subjects
Controls HD CAPD
IV=10 N=10 N=8
Essential AA 1001 119 713 129w 741 83k'
Branched-chain AA 406 54 310 69h 296 57"
Non-essential AA 1357 95 1356 182 1505 118
the endogenous synthesis of CSA and taurine, showed no change
in uremic patients, as compared to normal subjects (Table 2). This
is similar to other reports in the literature [4, 6, 10, [11. It has also
been reported that free cysteine [11, 13, 18, 251, free homocysteine
[11, 13, 14, 26], cysteine-homocysteine-mixed disulfide [11, 13, 26],
protein-bound cysteine and protein-bound homocysteine [11, 13]
are elevated in the plasma of untreated uremic patients and
dialyzed patients.
A single dialysis treatment (Table 2) significantly reduced the
plasma concentrations of taurine and CSA, while the methionine
concentrations remained unchanged during a single HD treat-
ment. However, earlier studies have shown a reduction in the
plasma concentrations of methionine at the end of HD treatment
[10, 111.
The concentration of taurine in the cells is high and it also has
a high concentration gradient between plasma and the cells [15].
An important question is whether low plasma taurine levels in
uremic patients are due to taurine depletion or to a redistribution
of taurine between the extracellular and intracellular compart-
ments. Bergstrom et al [18] reported that the plasma and muscle
intracellular taurine concentrations were reduced in uremic pa-
tients to about the same extent and it is unlikely that an abnormal
transmembrane gradient caused the reduction in plasma taurine
level. Lindholm et al [6] observed reduced intracellular taurine
levels and a correlation between the plasma and muscle taurine
concentrations in CAPD patients, indicating that the intracellular
taurine pool may be roughly estimated from measurements of
plasma taurine. Therefore, we may conclude that the low plasma
taurine levels in HD and CAPD patients in the present study
reflect intracellular taurine depletion.
MOller et al [27] reported that the taurine concentrations in
plasma and muscle were not significantly different in healthy
elderly subjects (52 to 77 years) compared with younger subjects
(20 to 36 years), although the values tended to be high in the older
age group. Hence, an age difference cannot explain the lower
plasma taurine levels in our patients than in the control subjects.
Our observation that the plasma taurine concentrations are low
in dialysis patients in the presence of normal concentrations of
methionine and high concentrations of CSA suggests that the
synthesis of taurine is inhibited by reduced activity of CSAD, the
rate-limiting enzyme for synthesis of taurine from CSA (Fig. 1).
Like several other enzymes in the transsulfuration pathway,
CSAD requires pyridoxal phosphate as a cofactor [16, 17], and
pyridoxine deficiency has been reported to he common in patients
with chronic renal failure [28]. Hence, pyridoxine deficiency may
contribute to reduced taurine synthesis in patients with renal
failure. However, this cause of reduced taurine synthesis is
unlikely in our dialysis patients, who were all taking daily vitamin
supplements containing 10 mg vitamin B6. It seems more likely
that uremic toxicity may play a role, either by inhibition of CSAD
activity or by reduction of its synthesis. CSA may also be
metabolized via the deamination pathway by aspartate amino-
transferase enzyme (Fig. 1). However, if this is the only mecha-
nism by which CSA accumulates in renal failure, one should not
expect to find reduced taurine levels.
A pertinent question in this context is whether the block
observed in taurine synthesis causes taurine depletion or whether
other factors are involved. It is generally assumed that the main
source of taurine in humans is a dietary intake of taurine and its
precursor amino acids. Dietary taurine has not proved to be
essential for adult humans [29], but low plasma taurine levels have
been noted in vegans [30], presumably due to a reduced intake of
taurine. Uremic patients often suffer from anorexia leading to a
reduced intake of protein; the most common source of protein is
meat, which is an important source of dietary taurine. Therefore,
it cannot be ruled out that a low dietary intake of taurine may
contribute to taurine depletion, the risk of which is increased
because of the reduced endogenous generation of taurine by the
transsulfuration pathway, as our results suggest. We observed
slightly reduced concentrations of serum albumin and plasma
essential and branched-chain amino acids in our patients, and it
cannot be excluded that they suffered from mild protein malnu-
trition, despite having a normal body mass index (Table 1).
However, the dietary protein intake, estimated from nPNA, was
on an average higher than I g/kg body wt/day, presumably
containing sufficient amounts of animal protein products (meat)
to provide adequate amounts of dietary taurine.
A contributing factor to taurine depletion may also be the
elimination of taurine by the dialysis procedures. In HD patients,
about 0.64 mmoles are lost during a single dialysis session [311.
Therefore, the average daily loss will be about 0.22 mmoles, if the
patient is dialyzed three times a week. In CAPD patients, the daily
dialytic loss of taurine is even smaller than that found in HD
patients [32, 33]. The HD patients in the present study were
functionally anephric and the CAPD patients also lacked a
life-supporting renal function.
In normal humans, the main route of elimination of taurine is
by renal excretion [34]. As shown in Table 3, the urinary excretion
of taurine in our control subjects was about 31 rmol per hour,
corresponding to about 0.74 mmol/day, which agrees with values
reported earlier [29]. This implies that the normal renal excretion
of taurine is considerably higher than the amount eliminated by
dialysis in renal failure patients, in whom the renal elimination is
nil or negligible. Hence, dialytic losses of taurine can only be of
minor importance for the development of taurinc depletion in
these patients.
Taurinc conjugates with bile acids, thus participating in the
enterohepatic circulation of these compounds [35]. In syndromes
of bacterial overgroth in the small intestine increased of decon-
jugation of bile acids occurs [351. Since abnormal colonization of
the small intestine by both anaerobic and aerobic bacteria has
been reported in uremia [361, it cannot be excluded that increased
deconjugation of bile acids and taurine may take place in dialysis
patients, thus contributing to the losses from the taurine pool.
One might expect that anephric dialysis patients with little, if
any, residual renal function, in whom the dialytic losses corre-
spond to only about one third of the normal renal elimination,
should accumulate taurine in the body fluids. Since this is
obviously not the case, but the opposite occurs, one may assume
Histidine and glycine were not included because they were not resolved
with the reversed-phase column used. Taurinc was not included.
Significant differences between patients and controls are marked P <
0.05, 'P < 0.01 and 'p < 0.001
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that the block in taurine synthesis from CSA that we found is
serious enough not only to prevent taurine accumulation, but also
to contribute to the development of taurine depletion, and the
dietary intake is insufficient to compensate for the reduction in
synthesis. The results suggest that endogenous generation of
taurine plays a more important role for sustenance of the normal
taurine pools in the body fluids of humans and that taurine may be
an essential nutrient in maintenance dialysis patients.
Taurine seems to have a functional role in promoting calcium
transport and calcium binding to membranes, it has a positive
inotropic effect on the heart, it has an antiarrhythmic and anti-
hypertensive effect, is involved in many metabolic responses in the
central nervous system, has an anticonvulsant action, it may have
an insulinogenic action and it is required for intact function of the
eyes [16, 37]. Our observations suggesting taurine depletion and a
block of taurine synthesis in uremic patients raise the question of
whether or not taurine depletion in uremia has clinical conse-
quences and whether supplementation with taurine may be ben-
eficial in such patients.
Acknowledgments
This study was supported by a grant from Baxter Healthcare Corpora-
tion, Deerfield, Illinois, USA. We are grateful to the nursing staff,
especially to Ms. Ulla Petersson and Ms. Inger Sjödin in the Department
of Renal Medicine, Huddinge University Hospital, and to Ms. Eva
Malmberg in the Kungsholm Dialysis Center in Stockholm. We also thank
the laboratory staff, Ms. Kristina Rustas and Ms. Monica Eriksson, in our
research laboratory.
Reprmt requests to Dr. J. Bergstrom, Divisions of Baxter Novum and Renal
Medicine K-56, Huddinge University Hospital, Karolinska Institute, S- 141 86
Huddinge, Sweden. E-mail: jonas.bergstrom(d)kfcnml3.hs.sll.se
References
I. BERGSTROM J, FURsr P, NOREE LO, VINNARS E: Intracellular free
amino acid in muscle tissue of patients with chronic uremia. The
effects of peritoneal dialysis of essential amino acids. Clin Sci Mo/Med
54:51—60, 1978
2. KOPPLE JD: Abnormal amino acid and protein metabolism in uremia.
Kidney mt 14:340—348, 1978
3. YOUNG GA, SWANEPOEL CR, CROFT MR, HoBsoN SM: Anthropom-
etry and plasma valine, amino acids and proteins in the nutritional
assessment of hemodialysis patients. Kidney mt 21:492—499, 1982
4. AIvESTRAND A, FURST P, BERGSTROM J: Plasma and muscle free
amino acids in uremia: Influence of nutrition with amino acids. Clin
Nephrol 18:297—305, 1982
5. ALvESTRAND A, FURST P, BERGSTROM J: Intracellular amino acids in
uremia. Kidney mt 24(Suppl 13):S9—S16, 1983
6. LINDHOLM B, ALVESTRAND A, FURST F, BERGSTROM J: Plasma and
muscle free amino acids during continuous ambulatory peritoneal
dialysis. Kidney In! 35:1219—1226, 1989
7. GULYASSY 1', AVIRAM A, PETERS J: Evaluation of protein require-
ments in uremia. Arch In! Med 26:855—859, 1970
S. Coisuos JR, A5AIQOR AM: Amino acids metabolism in uremic
patients. Clin Chim Acta 32:333—337, 1971
9. KLEINER MJ, TATE SS, SuI.IvAN MD, CIIAMI J: Vitamin B6 deficiency
in maintenance dialysis patients: Metabolic effect of repletion. Am J
C/in Nutr 61:743—749, 1980
10. FLUGEL LINK RM, JONES MR, KOPPIE JD: Red cell and plasma amino
acid concentration in renal failure. J Parenteral Enteral Nutr 7:450—
456, 1976
11. SMOLIN LA, LAIDLAW SA, KOPPIE JD: Altered plasma free and
protein-hound sulphur amino acids in patients undergoing mainte-
nance hemodialysis. Am J Clin Nutr 45:737—743, 1987
12. ROBINS J, MILEWCZYK BK, BOOTH EM, MALLICK NP: Plasma amino
acid abnormalities in chronic renal failure. C/in Chim Acta 42:215—
217, 1972
13. WILCKEN DLE, GUPTA VJ, REDDY SG: Accumulation of sulphur
containing amino acids including cysteine-homocysteine in patients on
maintenance hemodialysis. Clin Sci 58:427—430, 1980
14. CIIAUvEAU P, CHADEFAUX B, COUDE M, AUPETIT J, HANNEDOUCHE
T, KAMOUN P, JUNGERS P: Increased plasma homocysteine concen-
tration in patients with chronic renal failure. Miner Electrol Metab
18:196—198, 1992
15. JACOBSEN JG, SMITH LH: Biochemistry and physiology of taurine and
taurinc derivatives. Physiol Rev 48:424—511, 1968
16. HAYES KC, STURMAN JA: Taurine in metabolism. Ann Rev Nutr
1:401—425, 1981
17. STURMAN J, HAYES KC: The biology of taurine in nutrition and
development, in Advances in Nutritional Research, edited by DROPPER
HH, New York, Plenum Press, 1980, pp 231—299
18. BERGSTROM J, ALVESTRAND A, FURST F, LINDHOLM B: Sulphur amino
acids in plasma and muscle in patients with chronic renal failure:
Evidence for taurine depletion. J Intern Med 226:189—194, 1989
19. QURESI-II GA, QURESHI AR, BERGSTROM J: Quantitation of free
amino acids in plasma and muscle samples from healthy subjects and
uremic patients by high-performance liquid chromatography and
fluorescence detection. J Pharm Biomed Anal 7:377—384, 1989
20. JUNG BC, LAIDLAW SA, KOPPLE JD: Taurine levels in plasma and
blood cells in patients undergoing routine maintenance hcmodialysis.
Am J Kidney Dis 18/1:74—79, 1991
21. FARELL PC, GOTCFT F: Dialysis therapy guided by kinetic modelling:
Applications of variable-volume single-pool model of urea kinetics.
Second Australian Conference on Heat and Mass Transfer, 1977, pp
29—37
22. KOPPLE JD, JoNES MR, KESHAvIAH PR, BERGSTROM J, LINDSAY RM,
MORAN J, NOLPH KD, TEEHAN BP: A proposed glossary for dialysis
kinetics. Am J Kidney Dis 26:963—98 1, 1995
23. TRAUTWEIN EA, HAYES KC: Taurine concentration in plasma and
whole blood in humans: Estimation of error from intra- and interin-
dividual variation and sampling technique. Am J Clin Nutr 52:758—764,
1990
24. GODEL H, GRASER T, FOLDI P, PFAENDER P, FURST P: Measurement
of free amino acids in human biological fluids by high-performance
liquid chromatography. J Chromatogr 297:49—61, 1984
25. WRIGHT CE, TALIAN HH, LIN YY, GAULL GE: Taurine biological
update. Ann Rev Biochem 55:427—453, 1986
26. LAIDLAW SA, SMOLJN LA, DAVIDSON WD, KOPPLE JD: Sulfur amino
acids in maintenance hemodialysis patients. Kidney mt 32(Suppl
22):S191—S196, 1987
27. MOLLER P, BERGSTROM J, ERIKSSON 5, FURST P, HELLSTROM K: Effect
of ageing on free amino acids and electrolytes in leg skeletal muscle.
Clin Sci 56:427—432, 1979
28. KOPPLE J, MERCURIO K, BLUMENKRANTZ J: Daily requirement of
pyridoxine supplement in chronic renal failure. Kidney mt 19:694—704,
1981
29. HAYES KC: Taurine requirement in primates. Nutr Rev 43:65—70, 1985
30. LAIDLAW SA, SCHULTZ TD, CECCHINO RD, KOPPLE JD: Plasma and
urine taurine levels in vegans. Am J C/in Nutr 47:660—663, 1988
31. GUTIERREZ A, BERGSTROM J, AIvF:SnANo A: Hemodialysis-associ-
ated protein catabolism with and without glucose in the dialysis fluid.
Kidney mt 46:814—822, 1994
32. BOMBROS N, OREN A, MARLISS EB, ANDERSON GH, STEIN AN,
ORIoI'ouLos D: Plasma amino acid profiles and amino acid losses in
patients undergoing CAPD. Pent Dial Bull 2:27—32, 1982
33. GIORDANO C, DE SANTO N, COPODICASA G: Amino acids losses during
continuous ambulatory peritoneal dialysis. Clin Nephrol 14:230—232, 1980
34. SEGEL 5, THIER SO: Renal handling of amino acids, in Handbook of
Physiolo,ey, edited by OREOFF J, BERLINER RW, Washington DC,
American Physiological Society, 1973, pp 653— 676
35. HOFMANN AF: Enterohepatic circulation of bile acids, in Handbook of
Physiology. The Gastrointestinal System, edited by SCHULTZ SG Be-
thesda, American Physiological Society, 1989, pp 567—596
36. SIMENHOFF ML, SAUKKONEN JJ, BURKE JF, WESSON LG, SCHAEDLER
RW, GoRDoN SJ: Bacterial populations of the small intestine in
uremia. Nephron 22:63—68, 1978
37. HUXIABLE RJ: Physiological actions of taurine. Physiol Rev 72:101—
163, 1992
